| Previous Section | Index | Home Page |
2 May 2006 : Column 1530W—continued
Blood Products
Jenny Willott: To ask the Secretary of State for Health what imported blood products were licensed by the Medical Healthcare products Regulatory Authority between 1976 and 1990; on what date they were licensed; and if she will make a statement. [65510]
Jane Kennedy: A range of blood products which were manufactured outside of the United Kingdom, including human albumin, immunoglobulins, plasminogen, factor VIII and factor IX were authorised by the Department and its subsequent Next Steps Agency, the Medicines Control Agency, during the period 1976 to 1990. This information was derived from the current database held by the Medicines and Healthcare products Regulatory Agency (MHRA). The names of the products, the product licence number and date of authorisation are shown as follows:
Blood products that were licensed in the United Kingdom during 1976–90 and imported were manufactured in Austria or the United States of America. The following is a list currently held in the MHRA database.
2 May 2006 : Column 1531W
Data submitted in support of the applications were considered satisfactory with regard to quality, safety and efficacy requirements.
Bowel Cancer Screening
Mr. Baron: To ask the Secretary of State for Health what estimate she has made of the change in bowel cancer screening capacity in England since 1 April. [66896]
Ms Rosie Winterton: The national bowel cancer screening programme will be rolled out nationally over the next three years. We started the roll-out as promised in April. Capacity will be built up progressively over the next three years. It is too soon to estimate what changes in capacity have already occurred.
British Fluoridation Association
Susan Kramer: To ask the Secretary of State for Health how much funding her Department has given to the British Fluoridation Association in the last five years for which data is available. [65066]
Caroline Flint: Funding provided by the Department to the British Fluoridation Society in the last five years is shown in the following table.
| Funding (£) | |
|---|---|
| 2001–02 | 82,000 |
| 2002–03 | 84,050 |
| 2003–04 | 85,000 |
| 2004–05 | 87,000 |
| 2005–06 | 90,000 |
Cancer
Ms Diana R. Johnson: To ask the Secretary of State for Health how many patients normally resident in Hull North have been treated for cancer in the past 12 months. [65464]
Mr. Byrne: The information requested is shown in the table.
Notes:
Finished consultant episode (FCE)
A FCE is defined as a period of admitted patient care under one consultant within one health care provider. Please note that the figures do not represent the number of patients, as a person may have more than one episode of care within the year.
Patient counts
Patient counts are based on the unique patient identifier called the hospital episode statistics identifier (HESID). This identifier is derived based on patient's date of birth, postcode, sex, local patient identifier and NHS number, using an agreed algorithm. Where data is incomplete, HESID might erroneously link episodes or fail to recognise episodes for the same patient. Care is therefore needed, especially where duplicate records persist in the data. The patient count cannot be summed across a table where patients may have episodes in more than one cell.
Diagnosis (primary diagnosis)
The primary diagnosis is the first of up to 14 (seven prior to 2002–03) diagnosis fields in the HES data set and provides the main reason why the patient was in hospital.
PCT and strategic health authority (SHA) data quality
PCT and SHA data was added to historic data-years in the HES database using 2002–03 boundaries, as a one-off exercise in 2004. The quality of the data on PCT of treatment and SHA of treatment is poor in 1996–97, 1997–98 and 1998–99, with over a third of all finished episodes having missing values in these years. Data quality of PCT of general practice (GP) practice and SHA of GP practice in 1997–98 and 1998–99 is also poor, with a high proportion missing values where practices changed or ceased to exist. There is less change in completeness of the residence-based fields over time, where the majority of unknown values are due to missing postcodes on birth episodes. Users of time series analysis including these years need to be aware of these issues in their interpretation of the data.
Ungrossed data
Figures have not been adjusted for shortfalls in data that is the data is ungrossed.
Source:
Hospital Episode Statistics (HES), NHS Health and Social Care Information Centre.
2 May 2006 : Column 1532W
Capita Group
James Brokenshire: To ask the Secretary of State for Health how many contracts her Department holds with (a) Capita plc and (b) its subsidiaries which still have a potential duration of five years or more. [61467]
Mr. Byrne: There are currently no contracts with Capita plc and its subsidiaries which have a potential duration of five years or more.
Carers (Respite)
Mr. Lansley: To ask the Secretary of State for Health which (a) bodies and (b) budgets will bear the cost of respite support to be provided for carers as set out in paragraph 5.55 of the 'Our Health, Our Care, Our Say' Health White Paper. [65996]
2 May 2006 : Column 1533W
Mr. Byrne: We are currently exploring options to develop additional support to carers, including the provision of short-term, home-based respite support in crisis or emergency situations.
Carers already have the right to an assessment of their own needs and local authorities have responsibilities to meet those needs, including the provision of breaks from caring if necessary.
Clinical Trials
Mr. Amess: To ask the Secretary of State for Health what guidelines she has issued on the conduct of clinical trials in England and Wales. [65175]
Jane Kennedy: All clinical trials that are conducted in England and Wales are regulated by the Medicines for Human Use (Clinical Trials) Regulations 2004 which implemented the Clinical Trials Directive (2001/20/EC) into United Kingdom law. This directive came into force in the UK on 1 May 2004. At the time the legislation came into force, the Medicines and Healthcare products Regulatory Agency (MHRA) issued comprehensive guidance and advice on the new regulatory framework to all stakeholders including those involved in the conduct of clinical trials. The Department also issued specific guidance about sponsorship responsibilities in publicly funded trials under the new regulatory framework. The Department's research governance framework for health and social care which is the core standard for health care draws attention to the law regulating clinical trials and to the principles of good clinical practice. In addition, the European Commission has issued detailed guidance on the requirements under the directive.
| Next Section | Index | Home Page |